glp 1 period late Only one in 12 remain on a GLP-1 drug for obesity at three years Is Perimenopause Blunting Your GLP-1?

Lancet (London, England), 402 (10403), 705719

The trend is also evident in the fact that more people say they are using GLP - 1 drugs based on word of mouth or personal research in combination with a doctors recommendation, according to the survey, while those using them based solely on a doctors prescription declined among newer users

For patients on Medicare Part D, approval is usually granted through the end of the calendar year

FDA-approved GLP-1 products are currently indicated for: Type 2 diabetes management Chronic weight management Obesity treatment Cardiometabolic risk reduction in specific patient populations Long-term metabolic disease management These products have undergone extensive FDA review to demonstrate: Safety Efficacy Manufacturing quality Clinical effectiveness Product stability Benefit-risk assessment Compounded products, however, do not undergo the same FDA approval process

Whether this new class of medication shows superior cardioprotection is still under investigation